

## **Nanodrugs in oncology: more efficacious, safer or not?**

Pierre Attali

Hôpital Paul-Brousse, 12 avenue Paul-Vaillant-Couturier 94800 Villejuif

Nanodrugs are being developed with the clinical objective to be more beneficial (more efficacious and safer) than classical small molecule entities or monoclonal antibodies. They can be either totally new drugs with their specific clinical profile or nanoformulations of “old” drugs for repurposing or addressing the clinical concerns of old drugs. Most nanoformulations have been developed in oncology. Their development raises several unexpected issues needing to be carefully overcome, particularly in terms of short term and long term safety. This presentation shows some safety issues observed with a nanoformulation of doxorubicine in the treatment of primary liver cancer and solutions for addressing them.